← All trials
NCT05188326
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 28, 2010
- Primary completion
- Sep 27, 2021
- Completion date
- Sep 27, 2021
- First posted
- Jan 12, 2022
- Last posted
- Jan 28, 2022
- Enrollment
- 54
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Associazione Qol-oneLead sponsor
- QOL-ONE Associazione Culturale e di RicercaStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.